Certara

70 articles about Certara

• Certara to Report Fourth Quarter and Full Year 2021 Financial Results on March 1st, 2022

  2/8/2022

  Certara, Inc., a global leader in biosimulation, announced that it will release financial results for the fourth quarter and full year of 2021 after the market close on Tuesday, March 1st, 2022.

• Certara Announces FDA Renewal and Expansion of Certara’s Biosimulation Software for Reviewing Regulatory SubmissionsFDA holds more than 400 Simcyp™ and Phoenix™ software licenses across 12 divisions and offices

  12/21/2021

  Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that the U.S. Food and Drug Administration (FDA) has renewed and expanded its licenses of Certara’s proprietary biosimulation software, with more than 400 user licenses of Simcyp and Phoenix software.

• Certara Announces Release of Pinnacle 21 Enterprise SoftwareNew metrics and analytics capabilities enable informed decision making for biopharmaceutical clients

  12/13/2021

  Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced the feature release of Pinnacle 21 Enterprise 5.1.0, which updates the Company’s flagship software for preparing clinical trial data for biosimulation and regulatory submission.

• Certara to Host Investor Day on December 15, 2021

  12/8/2021

  Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, will host an Investor Day on Wednesday, December 15, 2021 from 3:00 PM to 6:00 PM ET in New York City.

• Certara Announces Release of Simcyp™ Simulator Version 21, Expanding Capabilities to Align with Recent Regulatory GuidancesSimcyp Simulator has been used to inform more than 250 label claims for 85+ novel drugs

  12/2/2021

  Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced the release of Simcyp Simulator Version 21, which updates the Company’s population-based modeling and simulation platform.

• Certara Announces Update of D360™ Scientific Informatics SoftwareNew capabilities increase efficiency in analyzing and developing small molecules and biologic drugs

  11/29/2021

  Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced the release of D360 version 21.5, an industry-leading scientific informatics software for discovery scientists to integrate many data sources and analyze small molecules and biologic drugs for fast, high-confidence go/no-go decisions.

• Certara Announces Closing of Public Offering of Common Stock - Nov 22, 2021

  11/22/2021

  Certara, Inc., a global leader in biosimulation, announced the closing of its underwritten public offering of 10,000,000 shares of its common stock by certain existing stockholders at a public offering price of $31.00 per share.

• Certara Announces Pricing of Public Offering of Common Stock - Nov 18, 2021

  11/18/2021

  Certara, Inc., a global leader in biosimulation, announced the pricing of its underwritten public offering of 10 million shares of its common stock by certain existing stockholders at a price to the public of $31.00 per share.

• Certara Announces Proposed Public Offering of Common Stock - Nov 15, 2021

  11/15/2021

  Certara, Inc., a global leader in biosimulation, announced a proposed underwritten public offering by certain selling stockholders of 10 million shares of its common stock pursuant to a registration statement filed with the Securities and Exchange Commission.

• Certara Reports Third Quarter 2021 Financial Results

  11/9/2021

  Certara, Inc., a global leader in biosimulation, reported its financial results for the third quarter of fiscal year 2021.

• Certara Appoints James E. Cashman III as Chairman of Board of Directors

  11/8/2021

  Certara, Inc., a global leader in biosimulation, announced that James E. Cashman III, a current Board member, will be appointed Chairman of the Board of Directors, effective as of December 1, 2021.

• Certara to Participate in Piper Sandler 33rd Annual Virtual Healthcare Conference

  11/3/2021

  Certara, Inc. today announced that William F. Feehery, Chief Executive Officer, and Andrew Schemick, Chief Financial Officer will participate in a fireside chat at the Piper Sandler 33rd Annual Virtual Healthcare Conference.

• Certara’s Simcyp™ COVID-19 Vaccine Model Wins R&D 100 AwardBiosimulation tool to conduct ‘what-if’ scenarios with virtual patients recognized in Software/Services category

  10/25/2021

  Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that its Simcyp COVID-19 Vaccine Model has won an R&D 100 Award, which recognizes the top 100 “R&D pioneers and their revolutionary ideas in science and technology” in the past year.

• Certara to Report Third Quarter 2021 Financial Results on November 9th, 2021

  10/19/2021

  Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will release financial results for the third quarter of 2021 after the market close on Tuesday, November 9th, 2021.

• Certara Appoints Patrick F. Smith to President of Integrated Drug Development

  10/12/2021

  Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced the appointment of Patrick F. Smith, Pharm.D. as president of Integrated Drug Development (IDD), reporting to CEO William F. Feehery.

• 

  BioSpace Movers & Shakers, Oct. 8

  10/8/2021

  Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

• Certara Announces Pricing of Public Offering of Common Stock

  9/8/2021

  Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced the pricing of its underwritten public offering of shares of its common stock by Certara and certain existing stockholders (“the selling stockholders”) at a price to the public of $31.00 per share.

• 

  Africa is the Next Frontier for Biosimulation, as Certara Trains Up Talent

  7/23/2021

  Biosimulation is integral to drug development today, with fierce competition for expert scientists to run the simulations and interpret the results. Craig Rayner, president of Certara, a biosimulation company, is turning to Africa to unlock an untapped reservoir of talent.
• 

  BioSpace Movers & Shakers, July 23

  7/23/2021

  Biopharma and life sciences organizations strengthen their leadership teams and boards with these Movers & Shakers.

• Certara to Present at the Barclays Global Healthcare Conference

  2/26/2021

  Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that William Feehery, CEO and Andrew Schemick, CFO will virtually present at the Barclays Global Healthcare Conference on Tuesday, March 9, 2021 at 11:30 a.m. ET.